LivaNova Swings to $273M Loss on Environmental Charge, Revenue Up 10%

TL;DR

**LivaNova's environmental liability is a massive hit, making their revenue growth look like a mirage; steer clear until the SNIA cloud clears.**

AI Summary

LivaNova PLC reported a significant net loss of $273.377 million for the nine months ended September 30, 2025, a stark contrast to the net income of $7.343 million in the prior year, primarily driven by a substantial SNIA environmental liability expense of $363.815 million. Despite this, net revenue increased by 10.25% to $1,027.132 million for the nine-month period, up from $931.607 million in 2024. Gross profit also saw a healthy rise to $700.097 million from $639.115 million. Operating income improved significantly, reaching $156.812 million for the nine months ended September 30, 2025, compared to $92.030 million in the same period last year. The company's cash and cash equivalents increased to $646.079 million as of September 30, 2025, from $428.858 million at December 31, 2024, while total current liabilities more than doubled to $827.588 million, largely due to the SNIA environmental liability. Long-term debt obligations decreased to $349.031 million from $549.624 million. The 2024 Restructuring Plan aims to enhance focus on Cardiopulmonary and Neuromodulation segments, which could impact future profitability.

Why It Matters

LivaNova's substantial net loss of $273.377 million, primarily due to the $363.815 million SNIA environmental liability, is a critical red flag for investors, overshadowing a solid 10.25% revenue growth. This legal overhang could divert significant capital and management attention, potentially hindering R&D and market expansion in competitive medical technology sectors like Cardiopulmonary and Neuromodulation. Employees might face uncertainty regarding future investments and strategic shifts, while customers could see impacts on product development timelines. The broader market will watch how LivaNova manages this liability, as it sets a precedent for environmental risk management in the MedTech industry.

Risk Assessment

Risk Level: high — The risk level is high due to the $363.815 million SNIA environmental liability expense, which caused a net loss of $273.377 million for the nine months ended September 30, 2025. This single event significantly impacted the company's financial position, increasing total current liabilities to $827.588 million from $392.125 million at December 31, 2024, indicating substantial short-term financial strain.

Analyst Insight

Investors should exercise extreme caution and consider reducing exposure to LIVN. The massive SNIA environmental liability represents a significant, immediate financial burden that could impact future profitability and strategic initiatives. Wait for clear evidence of how LivaNova plans to mitigate this liability and return to sustained profitability before considering any new investment.

Financial Highlights

revenue

$1,027.132M

operating Margin

15.27%

total Assets

$2,507,996M

total Debt

$349.031M

net Income

$ (273.377M)

eps

$ (5.01)

gross Margin

68.17%

cash Position

$646.079M

revenue Growth

+10.25%

Revenue Breakdown

Key Numbers

• $273.377M — Net loss for nine months ended Sep 30, 2025 (Significant decline from $7.343M net income in prior year, primarily due to environmental liability.)
• $363.815M — SNIA environmental liability expense (Primary driver of the net loss for the nine months ended September 30, 2025.)
• $1,027.132M — Net revenue for nine months ended Sep 30, 2025 (Increased by 10.25% from $931.607M in the prior year, showing underlying business growth.)
• $156.812M — Operating income for nine months ended Sep 30, 2025 (Increased significantly from $92.030M in the prior year, indicating operational improvements before the environmental charge.)
• $646.079M — Cash and cash equivalents as of Sep 30, 2025 (Increased from $428.858M at December 31, 2024, providing liquidity despite the loss.)
• $827.588M — Total Current Liabilities as of Sep 30, 2025 (More than doubled from $392.125M at December 31, 2024, largely due to the SNIA liability.)
• $349.031M — Long-term debt obligations as of Sep 30, 2025 (Decreased from $549.624M at December 31, 2024, improving the long-term debt profile.)
• 54,605,527 — Ordinary Shares outstanding on Oct 29, 2025 (Reflects the total number of shares in circulation.)
• $0.49 — Diluted income per share for Q3 2025 (Decreased from $0.60 in Q3 2024, reflecting reduced quarterly profitability.)
• ($5.01) — Diluted loss per share for nine months ended Sep 30, 2025 (Significant decline from $0.13 income per share in prior year, driven by the SNIA liability.)

Key Players & Entities

• LivaNova PLC (company) — Registrant for the 10-Q filing
• Goldman Sachs Bank USA (company) — First Lien Administrative Agent for the 2021 First Lien Credit Agreement
• SNIA S.p.A. (company) — Party involved in the SNIA environmental litigation
• Sorin S.p.A. (company) — Party involved in the 2016 Court of Milan decision
• U.S. Securities and Exchange Commission (regulator) — Recipient of the 10-Q filing
• Nasdaq Global Select Market (company) — Exchange where LivaNova's Ordinary Shares are registered
• LivaNova USA, Inc. (company) — Wholly-owned subsidiary of LivaNova PLC
• Barclays Bank Ireland PLC (company) — Financial institution mentioned in the definitions
• U.S. Centers for Medicare & Medicaid Services (regulator) — Approves RECOVER study protocol
• ALung Technologies, Inc. (company) — Company developing advanced circulatory support systems

FAQ

Risk Factors

• SNIA Environmental Liability [high — legal]: A substantial $363.815 million expense related to the SNIA environmental liability significantly impacted the nine-month net loss. This contingent liability represents a major financial risk and uncertainty for the company.
• Increased Current Liabilities [high — financial]: Total current liabilities more than doubled to $827.588 million as of September 30, 2025, primarily due to the SNIA environmental liability. This sharp increase strains short-term financial flexibility.
• Restructuring Plan Impact [medium — operational]: The 2024 Restructuring Plan aims to enhance focus on Cardiopulmonary and Neuromodulation segments. While intended to improve efficiency, such plans carry inherent risks of execution challenges and potential short-term disruptions to operations and profitability.
• Environmental Compliance [medium — regulatory]: The significant SNIA environmental liability suggests potential past non-compliance or ongoing environmental remediation obligations. Failure to meet future environmental regulations could lead to further financial penalties and operational disruptions.

Industry Context

LivaNova operates in the highly competitive medical technology sector, specifically in Cardiopulmonary and Neuromodulation. The industry is characterized by rapid innovation, stringent regulatory oversight (FDA, EMA), and a need for significant R&D investment. Companies face pressure to demonstrate clinical efficacy and cost-effectiveness to gain market share and reimbursement.

Regulatory Implications

The substantial SNIA environmental liability highlights potential regulatory scrutiny regarding environmental compliance. The company must ensure adherence to evolving environmental regulations across its global operations to avoid future penalties and reputational damage. Compliance with medical device regulations (e.g., FDA, MDR) remains critical for product approval and market access.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 financial results reported — Reported a significant net loss of $273.377M, largely due to a $363.815M SNIA environmental liability, despite a 10.25% increase in net revenue to $1,027.132M.
• 2025-10-29: Ordinary Shares outstanding reported — 54,605,527 ordinary shares outstanding provide a basis for per-share calculations and investor ownership.

Glossary

SNIA environmental liability expense

A charge recorded for potential costs associated with environmental remediation or compliance obligations related to the SNIA (likely a former entity or site). (This was the primary driver of the significant net loss for the nine months ended September 30, 2025, amounting to $363.815 million.)

Operating income

Profitability from a company's core business operations before accounting for interest, taxes, and other non-operating income or expenses. (Improved to $156.812 million for the nine months ended September 30, 2025, indicating strong underlying operational performance despite the large environmental charge.)

Diluted income (loss) per share

The earnings or loss per share after accounting for all potential dilutive securities, such as stock options and convertible bonds. (For the nine months ended September 30, 2025, this was a loss of ($5.01) per share, a sharp decline from the prior year's income, primarily due to the environmental liability.)

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair value of its identifiable net assets. (Stands at $791.034 million as of September 30, 2025, representing a significant portion of the company's assets, reflecting past acquisitions.)

Year-Over-Year Comparison

Compared to the prior year, LivaNova reported a significant shift from net income of $7.343 million to a net loss of $273.377 million for the nine months ended September 30, 2025. This was primarily driven by a $363.815 million SNIA environmental liability expense. Despite this, net revenue saw a healthy increase of 10.25% to $1,027.132 million, and operating income improved to $156.812 million, indicating strong underlying operational performance. Total current liabilities more than doubled to $827.588 million, largely due to the environmental provision, while long-term debt decreased significantly.

Key Financial Figures

• $287.5 million — 025 Director Incentive Plan 2025 Notes $287.5 million aggregate principal amount 3.00% unsecu
• $230.0 million — es Repurchase Transaction Repurchase of $230.0 million aggregate principal amount of the 2025
• $345.0 million — tain financial institutions 2029 Notes $345.0 million aggregate principal amount 2.50% unsecu
• $50.0 million — l in Milan Delayed Draw Term Facility $50.0 million delayed draw term facility under the 20
• $300.0 million — ed July 6, 2022 Initial Term Facility $300.0 million term facility under the 2021 First Lien

Filing Documents

• livn-20250930.htm (10-Q) — 1601KB
• livn-2025930xex311.htm (EX-31.1) — 9KB
• livn-2025930xex312.htm (EX-31.2) — 9KB
• livn-2025930xex321.htm (EX-32.1) — 8KB
• livn-20250930_g1.jpg (GRAPHIC) — 34KB
• 0001639691-25-000150.txt ( ) — 9541KB
• livn-20250930.xsd (EX-101.SCH) — 45KB
• livn-20250930_cal.xml (EX-101.CAL) — 91KB
• livn-20250930_def.xml (EX-101.DEF) — 297KB
• livn-20250930_lab.xml (EX-101.LAB) — 612KB
• livn-20250930_pre.xml (EX-101.PRE) — 505KB
• livn-20250930_htm.xml (XML) — 1924KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 1.

Financial Statements (unaudited)

Financial Statements (unaudited) 6 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 29 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 36 4.

Controls and Procedures

Controls and Procedures 36

OTHER INFORMATION

PART II. OTHER INFORMATION 1.

Legal Proceedings

Legal Proceedings 37 1A.

Risk Factors

Risk Factors 37 2. Unregistered Sales of Equity Securities and Use of Proceeds 37 3. Defaults Upon Senior Securities 37 4. Mine Safety Disclosures 37 5. Other Information 37 6. Exhibits 38

Signatures

Signatures 39 DEFINITIONS In this Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, the following terms and abbreviations have the meanings listed below. "LivaNova" and the "Company" refer to LivaNova PLC and its consolidated subsidiaries. Abbreviation Definition 2015 Plan LivaNova PLC 2015 Incentive Award Plan 2016 Decision Decision by the Court of Milan in 2016 to dismiss all legal actions of SNIA and of the Public Administrations and to further require the Public Administrations to pay Sorin 292,000 for legal fees 2021 First Lien Credit Agreement First Lien Credit Agreement between LivaNova PLC and its wholly-owned subsidiary, LivaNova USA, Inc., and Goldman Sachs Bank USA, as First Lien Administrative Agent and First Lien Collateral Agent, entered into on August 13, 2021 2024 Form 10-K LivaNova PLC's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 25, 2025 2024 Restructuring Plan A plan, initiated during the first quarter of 2024, to enhance LivaNova's focus on its core Cardiopulmonary and Neuromodulation segments 2025 Capped Calls Privately-negotiated capped call transactions entered into with certain financial institutions 2025 Director Incentive Plan LivaNova PLC 2025 Director Incentive Plan 2025 Notes $287.5 million aggregate principal amount 3.00% unsecured cash exchangeable senior notes due December 15, 2025, by private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act, issued by LivaNova USA on June 17, 2020 2025 Notes Repurchase Transaction Repurchase of $230.0 million aggregate principal amount of the 2025 Notes in privately-negotiated transactions from proceeds from the issuance of the 2029 Notes 2029 Capped Calls Privately-negotiated capped call transactions entered into with certain financial institutions 2029 Notes $345.0 million aggregate principal amount 2.50% unsecured convertible senior notes due 2029 by private placeme

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS LIVANOVA PLC AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) (UNAUDITED) (In thousands, except per share amounts) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Net revenue $ 357,753 $ 318,120 $ 1,027,132 $ 931,607 Cost of sales 112,898 97,091 327,035 292,492 Gross profit 244,855 221,029 700,097 639,115 Operating expenses: Selling, general, and administrative 138,522 127,426 405,448 378,238 Research and development 48,577 48,805 133,641 139,206 Other operating expense 3,744 9,180 4,196 29,641 Operating income 54,012 35,618 156,812 92,030 SNIA environmental liability expense ( 1,745 ) — ( 363,815 ) — Interest expense ( 10,863 ) ( 15,878 ) ( 38,429 ) ( 47,303 ) Loss on debt extinguishment — — ( 2,651 ) ( 25,482 ) Foreign exchange and other income/(expense) ( 7,493 ) 24,701 ( 332 ) 12,585 Income (loss) before income tax 33,911 44,441 ( 248,415 ) 31,830 Income tax expense 7,114 11,525 24,921 24,469 (Loss) income from equity method investments ( 13 ) 37 ( 41 ) ( 18 ) Net income (loss) $ 26,784 $ 32,953 $ ( 273,377 ) $ 7,343 Basic income (loss) per share $ 0.49 $ 0.61 $ ( 5.01 ) $ 0.14 Diluted income (loss) per share $ 0.49 $ 0.60 $ ( 5.01 ) $ 0.13 Shares used in computing basic income (loss) per share 54,630 54,352 54,529 54,194 Shares used in computing diluted income (loss) per share 55,153 54,585 54,529 54,526 See accompanying notes to the condensed consolidated financial statements. 6 LIVANOVA PLC AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) (In thousands) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Net income (loss) $ 26,784 $ 32,953 $ ( 273,377 ) $ 7,343 Other comprehensive (loss) income: Foreign currency translation adjustment ( 2,605 ) 26,116 85,678 1,180 Other comprehensive (loss) income, net of tax ( 2,605 ) 26,116 85,678 1,180 Comprehensive i